Intravenous delivery of camptothecin-loaded PLGA nanoparticles for the treatment of intracranial glioma

International Journal of Pharmaceutics

Volumn 479, Issue 2, 2015, Pages 374-380

  Householder, Kyle T ^a,b   Diperna, Danielle M ^a   Chung, Eugene P ^a,b   Wohlleb, Gregory M ^a,b   Dhruv, Harshil D ^c   Berens, Michael E ^c   Sirianni, Rachael W ^a,b  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b Arizona State University   (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

Camptothecin; GL261; Glioblastoma; Intracranial; Nanoparticles; PLGA

Indexed keywords

CAMPTOTHECIN; GLYCOLIC ACID DERIVATIVE; HISTONE H2AX; NANOPARTICLE; POLY (LACTIC CO GLYCOLIC ACID); UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG CARRIER; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; GLIOBLASTOMA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR LOCALIZATION; ANIMAL; BRAIN NEOPLASMS; C57BL MOUSE; CHEMICAL PHENOMENA; CHEMISTRY; FEASIBILITY STUDY; GLIOMA; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; SURVIVAL RATE; TIME;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CAMPTOTHECIN; DRUG CARRIERS; FEASIBILITY STUDIES; GLIOMA; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INJECTIONS, INTRAVENOUS; LACTIC ACID; MICE; MICE, INBRED C57BL; NANOPARTICLES; POLYGLYCOLIC ACID; SURVIVAL RATE; TIME FACTORS;

EID: 84921059241     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.01.002     Document Type: Article

References (32)

1. M.G. Abdelwahab, T. Sankar, M.C. Preul, and A.C. Scheck Intracranial Implantation with subsequent 3D in vivo bioluminescent imaging of murine gliomas J. Vis. Exp. 2011 10.3791/3403
2. S. Acharya, and S.K. Sahoo PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect Adv. Drug Deliv. Rev. 63 2011 170 183 10.1016/j.addr.2010.10.008 EPR effect based drug design and clinical outlook for enhanced cancer chemotherapy
3. Y. Cirpanli, E. Bilensoy, A.L. Dogan, and S. Calis Development of polymeric and cyclodextrin nanoparticles for camptothecin delivery J. Controlled Release 148 2010 e21 e23 10.1016/j.jconrel.2010.07.034 11th European Sumposium on Controlled Drug Delivery
4. A.J. Clark, M. Safaee, T. Oh, M.E. Ivan, V. Parimi, R. Hashizume, T. Ozawa, C.D. James, O. Bloch, and A.T. Parsa Stable luciferase expression does not alter immunologic or in vivo growth properties of GL261 murine glioma cells J. Transl Med. 2014 12 10.1186/s12967-014-0345-4
5. M.E. Davis The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic Mol Pharm. 6 2009 659 668 10.1021/mp900015y
6. C.M. Dawidczyk, L.M. Russell, and P.C. Searson Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments Chem. Eng. 2 2014 69 10.3389/fchem.2014.00069
7. Y. Deng, J.K. Saucier-Sawyer, C.J. Hoimes, J. Zhang, Y.-E. Seo, J.W. Andrejecsk, and W.M. Saltzman The effect of hyperbranched polyglycerol coatings on drug delivery using degradable polymer nanoparticles Biomaterials 35 2014 6595 6602 10.1016/j.biomaterials.2014.04.038
8. H.D. Dhruv, W.S. McDonough Winslow, B. Armstrong, S. Tuncali, J. Eschbacher, K. Kislin, J.C. Loftus, N.L. Tran, and M.E. Berens Reciprocal activation of transcription factors underlies the dichotomy between proliferation and invasion of glioma cells PLoS ONE 8 2013 e72134 10.1371/journal.pone.0072134
9. R. Dinarvand, N. Sepehri, S. Manoochehri, H. Rouhani, and F. Atyabi Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents Int. J. Nanomedicine 6 2011 877 895 10.2147/IJN.S18905
10. J. Fang, H. Nakamura, and H. Maeda The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect Adv. Drug Deliv. Rev. 63 2011 136 151 10.1016/j.addr.2010.04.009 EPR effect based drug design and clinical outlook for enhanced cancer chemotherapy
11. S.B. Fox, K.C. Gatter, R. Bicknell, J.J. Going, P. Stanton, T.G. Cooke, and A.L. Harris Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer Cancer Res. 53 1993 4161 4163
12. H.S. Friedman, T. Kerby, and H. Calvert Temozolomide and treatment of malignant glioma Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 6 2000 2585 2597
13. T. Furuta, H. Takemura, Z.-Y. Liao, G.J. Aune, C. Redon, O.A. Sedelnikova, D.R. Pilch, E.P. Rogakou, A. Celeste, H.T. Chen, A. Nussenzweig, M.I. Aladjem, W.M. Bonner, and Y. Pommier Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes J. Biol. Chem. 278 20 2003 303 20312 10.1074/jbcM300198200
14. K. Greish Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting S.R. Grobmyer, B.M. Moudgil, Cancer Nanotechnology, Methods in Molecular Biology 2010 Humana Press pp 25 37
15. S.A. Grossman, and J.F. Batara Current management of glioblastoma multiforme Semin. Oncol. 31 2004 635 644 10.1053/j.seminoncol.2004.07.005 Brain tumors
16. H. Han, and M.E. Davis Single-antibody, targeted nanoparticle delivery of camptothecin Mol. Pharm. 10 2013 2558 2567 10.1021/mp300702x
17. J. Hrkach, D.V. Hoff, M.M. Ali, E. Andrianova, J. Auer, T. Campbell, D.D. Witt, M. Figa, M. Figueiredo, A. Horhota, S. Low, K. McDonnell, E. Peeke, B. Retnarajan, A. Sabnis, E. Schnipper, J.J. Song, Y.H. Song, J. Summa, D. Tompsett, G. Troiano, T.V.G. Hoven, J. Wright, P. LoRusso, P.W. Kantoff, N.H. Bander, C. Sweeney, O.C. Farokhzad, R. Langer, and S. Zale Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile Sci. Transl. Med. 4 2012 128ra39 10.1126/scitranslmed.3003651
18. V.L. Jacobs, P.A. Valdes, W.F. Hickey, and J.A. De Leo Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model ASN NEURO 2011 3 10.1042/AN20110014
19. J. Lu, X. Chuan, H. Zhang, W. Dai, X. Wang, X. Wang, and Q. Zhang Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo Int. J. Pharm. 471 2014 525 535 10.1016/j.ijpharm.2014.05.032
20. R.L. McCall, and R.W. Sirianni PLGA nanoparticles formed by single- or double-emulsion with vitamin E-TPGS J. Vis. Exp. 2013 10.3791/51015
21. R.L. McCall, J. Cacaccio, E. Wrabel, M.E. Schwartz, T.P. Coleman, and R.W. Sirianni Pathogen-inspired drug delivery to the central nervous system Tissue Barriers 2014 e944449 10.4161/21688362.2014.944449
22. P.A. McCarron, W.M. Marouf, D.J. Quinn, F. Fay, R.E. Burden, S.A. Olwill, and C.J. Scott Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells Bioconjug. Chem. 19 2008 1561 1569 10.1021/bc800057g
23. K. Mross, H. Richly, N. Schleucher, S. Korfee, M. Tewes, M.E. Scheulen, S. Seeber, T. Beinert, M. Schweigert, U. Sauer, C. Unger, D. Behringer, E. Brendel, C.G. Haase, D. Voliotis, and D. Strumberg A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors Ann. Oncol. 15 2004 1284 1294 10.1093/annonc/mdh313
24. E.W. Newcomb, and D. Zagzag The murine GL261 glioma experimental model to assess novel brain tumor treatments E.G. Meir, CNS Cancer, Cancer Drug Discovery and Development 2009 Humana Press 227 241
25. T. Oh, S. Fakurnejad, E.T. Sayegh, A.J. Clark, M.E. Ivan, M.Z. Sun, M. Safaee, O. Bloch, C.D. James, and A.T. Parsa Immunocompetent murine models for the study of glioblastoma immunotherapy J. Transl. Med. 12 2014 107 10.1186/1479-5876-12-107
26. U. Prabhakar, H. Maeda, R.K. Jain, E.M. Sevick-Muraca, W. Zamboni, O.C. Farokhzad, S.T. Barry, A. Gabizon, P. Grodzinski, and D.C. Blakey Challenges and key considerations of the enhanced permeability and retention (EPR) effect for nanomedicine drug delivery in oncology Cancer Res. 73 2013 2412 2417 10.1158/0008-5472CAN-12-4561
27. A.J. Sawyer, J.K. Saucier-Sawyer, C.J. Booth, J. Liu, T. Patel, J.M. Piepmeier, and W.M. Saltzman Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors Drug Deliv. Transl. Res. 1 2011 34 42 10.1007/s13346-010-0001-3
28. A.M. Seligman, M.J. Shear, and L. Alexander Studies in carcinogenesis: VIII. Experimental production of brain tumors in mice with methylcholanthrene Am. J Cancer 37 1939 364 395 10.1158/ajc.1939.364
29. T. Szatmári, K. Lumniczky, S. Désaknai, S. Trajcevski, E.J. Hídvégi, H. Hamada, and G. Sáfrány Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy Cancer Sci. 2006 546 553 10.1111/j1349-7006.2006.00208.x
30. G. Tosi, B. Bortot, B. Ruozi, D. Dolcetta, M.A. Vandelli, F. Forni, and G.M. Severini Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier Curr. Med. Chem. 20 2013 2212 2225
31. L.-J. Yang, C.-F. Zhou, and Z.-X. Lin Temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme: a systematic review Cancer Invest. 32 2014 31 36 10.3109/07357907.2013.861474
32. J. Yao, Y. Li, X. Sun, F.Z. Dahmani, H. Liu, and J. Zhou Nanoparticle delivery and combination therapy of gambogic acid and all-trans retinoic acid Int. J. Nanomed. 9 2014 3313 3324 10.2147/IJN.S62793